Buy & Sell Inovio Pharmaceuticals Inc (INO) – Inovio Pharmaceuticals Inc Price Today
Aura AI Summary
Key Stats
- $100.37MMarket Cap
- HealthSector
- -44.44%3M Drawdown
- $71.39MEnterprise Value
- -Dividend Yield
- 96% Buy | 4% SellTrading Activity
- 39 daysTypical Hold Time
Inovio Pharmaceuticals Inc (INO) is currently valued at a market capitalization of $100.37M, with an enterprise value of $71.39M. Over the past 52 weeks, Inovio Pharmaceuticals Inc has traded between a low of $1.05 and a high of $2.87, highlighting its annual price range. Over the past three months, Inovio Pharmaceuticals Inc has recorded a drawdown of -44.44%, reflecting recent price volatility. On average, investors hold Inovio Pharmaceuticals Inc for approximately 39 days, indicating typical investor behavior on the platform.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Most Recent News
Victoria’s Secret highlights strong turnaround and urges shareholders to support current board amid activist challenge
Victoria’s Secret & Co. released an investor presentation showcasing its significant operational improvements and financial momentum under CEO Hillary Super and the Path to Potential strategy since 2021. The company emphasized its refreshed leadershi...

US Golden Dome missile defense plan faces criticism over cost and arms race risks.
The US Golden Dome missile-defense system, designed to protect against ballistic, hypersonic, and cruise missiles, is under fire from Democrats and arms-control advocates. Critics warn it could cost over $1 trillion in 20 years, potentially trigger a...

Anthropic on track for $10.9B Q2 revenue, aiming for first profitable quarter
Anthropic is set to generate $10.9 billion in revenue for the second quarter, more than doubling its $4.8 billion in Q1 sales, potentially marking its first profitable quarter. The AI company, known for its Claude models, has seen rapid growth and is...
